LENZ Therapeutics, Inc.(US:LENZ) Globenewswire·2026-01-07 22:08Core Insights - LENZ Therapeutics launched VIZZ™ (aceclidine ophthalmic solution) 1.44% in October 2025, marking it as the first and only aceclidine-based eye drop for presbyopia treatment, with broad availability by mid-November 2025 [1][5] - The company reported approximately $1.6 million in net product revenue and over 20,000 prescriptions filled in Q4 2025, indicating strong initial market acceptance [1][7] - More than 6,500 unique eye care professionals (ECPs) prescribed VIZZ, with over 55% prescribing it multiple times, reflecting early confidence in the product [2][7] Commercial Highlights - The first commercial sale of VIZZ occurred in October 2025, with full multi-channel access established through e-pharmacy and nearly all retail pharmacies by mid-November 2025 [7] - The rapid uptake by prescribing ECPs is notable, with over 6,500 unique ECPs participating in the prescription process [7] Corporate Updates - In January 2026, LENZ announced an exclusive commercialization partnership for VIZZ with Lunatus in the Middle East, which includes upfront, regulatory, and commercial milestone payments, along with a significant revenue share [4] - This partnership represents the fourth commercialization agreement for VIZZ outside the United States, indicating the company's strategy to expand its international presence [4] Product Information - VIZZ is designed to restore clear near vision for up to 10 hours and is preservative-free, provided in single-dose vials [9] - The product is indicated for age-related blurry near vision (presbyopia) in adults, a condition affecting approximately 1.8 billion people globally [5][10]